Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing

Sangamo Therapeutics, Inc. , a clinical-stage genomic medicine company and Chroma Medicine, Inc. , a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced...

Related Keywords

Sangamo Zfps ,Jason Fontenot ,Vic Myer ,Exchange Commission ,Nasdaq ,Sangamo Therapeutics Inc ,Linkedin ,Chroma Medicine Inc ,Twitter ,Sangamo Therapeutics ,Chroma Medicine ,Chief Scientific Officer ,Annual Report ,Quarterly Report ,Markets ,